

8. Literaturverzeichnis

- 1 G. Agnelli, P. Parise, M. Levi, B. Cosmi and G. G. Nenci. Effects of desmopressin on hemostasis in patients with liver cirrhosis. *Haemostasis*. 25(5):241-247, 1995.
- 2 A. Alanay, E. Acaroglu, O. Ozdemir, O. Ercelen, E. Bulutcu and A. Surat. Effects of deamino-8-D-arginin vasopressin on blood loss and coagulation factors in scoliosis surgery. A double-blind randomized clinical trial. *Spine*. 24(9):877-882, 1999.
- 3 J. P. Allen, R. Z. Litten, R. F. Anton and G. M. Cross. Carbohydrate-deficient transferrin as a measure of immoderate drinking: remaining issues. *Alcohol Clin Exp Res*. 18(4):799-812, 1994.
- 4 S. Andréason, Allebeck P. Hospital admission for somatic care among young men: the role of alcohol. *Br J Addict*. 85(7):935-941, 1990.
- 5 C. L. Balduini, P. Noris, S. Belletti, P. Spedini and G. Gamba. In vitro and in vivo effects of desmopressin on platelet function. *Haematologica*. 84(10):891-896, 1999.
- 6 D. G. Bichet, M. Razi, M. Lonergan, M. F. Arthus, V. Papukna, C. Kortas and J. N. Barjon. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. *N Engl J Med*. 318(14):881-887, 1988.
- 7 M. Booke, F. Hinder, H. Van Aken, M. Erren, A. Reich, C. Hönemann und H.G. Bone. Verfahrenstechniken zur Reduktion des postoperativen Blutverlustes. *Anästhesiologie & Intensivmedizin* 7/8 (40):535-538, 1999
- 8 F. Booth, M. J. Allington and S. A. Cederholm-Williams. An in vitro model for the study of acute release of von Willebrand factor from human endothelial cells. *Br J Haematol*. 67(1):71-78, 1987.
- 9 V. Borcea, P. Nawroth: TIM, Kapitel 4.18, Gerinnungsdefekte, s 960 - 967, Thieme, 1999.

- 10 J. P. Breuer, T. Neumann, A. Heinz, W. J. Kox and C. Spies. [The alcoholic patient in the daily routine]. *Wien Klin Wochenschr.* 115(17-18):618-633, 2003.
- 11 G. Buehringer, R. Simon. Die gefährlichste psychoaktive Substanz – Epidemiologie zum Konsum und Missbrauch von Alkohol. *Psycho.* 18(3): 156-162, 1992.
- 12 A. Casanato, E. Pontata, A. Bertomoro, F. Sartorello, M. G. Cattini and A. Girolami. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? *Br J Haematol.* 112(3):578-83, 2001.
- 13 M. Cattaneo, P. M. Tenconi, I. Alberca, V. V. Garcia and P. M. Mannucci. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. *Thromb Haemost.* 64(3):358-360, 1990.
- 14 M. Cattaneo and P. M. Mannucci. Desmopressin and blood loss after cardiac surgery. *Lancet.* 342(8874):812, 1993.
- 15 M. Cattaneo. Desmopressin in the treatment of patients with defects of platelet function. *Haematologica.* 87(11):1122-1124, 2002.
- 16 W. J. Chng, C. Y. C. Yip, M. B. Baliwag and T. Liu. Differential effect of the ABO blood group on von Willebrand factor collagen binding activity and ristocetin cofactor assay. *Blood Coagul Fibrinolysis.* 16(1):75-78, 2005.
- 17 H. Demiroglu, I. Barista, M. Gursoy, O. Oymak and S. Dundar. The effect of desmopressin on platelet aggregation defect in systemic amyloidosis: a preliminary report. *Eur J Haematol.* 56(5):283-286, 1996.
- 18 O. Elmer, G. Goransson and E. Zoucas. Impairment of primary hemostasis and platelet function after alcohol ingestion in man. *Haemostasis.* 14(2):223-228, 1984.
- 19 G. Escolar, A. Cases, M. Vinas, M. Pino, J. Calls, I. Cirera and A. Ordinas. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. *Haematologica.* 84(7):614-619, 1999.

- 20 J. A. Ewing. Detecting alcoholism. The CAGE questionnaire. *JAMA*. 252(14):1905-1907, 1984.
- 21 E. J. Favaloro. Von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey. *Semin Thromb Hemost*. 28(2):191-202, 2002.
- 22 A. B. Federici, S. D. Berkowitz, A. Lattuada and P. M. Mannucci. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. *Blood*. 81(3):720-725, 1993.
- 23 D. Ferro, C. Quintarelli, A. Lattuada, R. Leo, M. Alessandroni, P. M. Mannucci and F. Violi. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. *Hepatology*. 23(6):1377-1383, 1996.
- 24 T. Hackmann, R. D. Gascoyne, S. C. Naiman, G. H. Growe, L. D. Burchill, W. R. Jamieson, S. B. Sheps, M. T. Schechter and G. E. Townsend. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. *N Engl J Med*. 321(21):1437-1443, 1989.
- 25 S. Hashemi, D. S. Palmer, M. T. Aye and P. R. Ganz. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. *J Cell Physiol*. 154(3):496-505, 1993.
- 26 M. J. Hollestelle, T. Thinnis, K. Crain, A. Stiko, J. K. Kruijt, T. J. van Berkel, D. J. Loskutoff and J. A. van Mourik. Tissue distribution of factor VIII gene expression in vivo- a closer look. *Thromb Haemost*. 86(3):855-861, 2001.
- 27 A. Kallas and T. Talpsep. The von Willebrand factor collagen-binding activity assay: clinical application. *Ann Hematol*. 80(8):466-471, 2001.
- 28 S. Kaufman, M. Stewart and P. A. Gordon. Evaluation of hemostatic activity of desamino-D-arginine vasopressin (DDAVP) in uremic rats. *Thromb Res*. 73(1):53-59, 1994.

- 29 J. E. Kaufmann, A. Oksche, C. B. Wollheim, G. Gunther, W. Rosenthal and U. M. Vischer. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. *J Clin Invest.* 106(1):107-116, 2000.
- 30 N. L. Koblinsky, J. J. Doyle, E. D. Israels, J. S. Winter, M. S. Cheang, R. D. Walker and A. J. Bishop. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus. *Lancet.* 1(8441):1293-1294, 1985.
- 31 N. L. Koblinsky, R. M. Letts, L. R. Patel, E. D. Israels, R. C. Monson, N. Schwetz and M. S. Cheang. 1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. *Ann Intern Med.* 107(4):446-450, 1987.
- 32 T. Kovesi and D. Royston. Pharmacological approaches to reducing allogeneic blood exposure. *Vox Sang.* 84(1):2-10, 2003.
- 33 R. Lakshman, M. Tsutsumi, P. Ghosh, s. Takase, H. Anni, o. Nikolaeva, Y. Israel, R. F. Anton, O. M. Lesch, A. Helander, G. Erikson, J-O. Jeppson, P. Marmillot and M. N. Rao. Alcohol Biomarkers: Clinical Significance and Biochemical Basis. *Alcohol Clin Exp Res.* 25(5 Suppl ISBRA):67S-70S, 2001.
- 34 S. Lethagen and I. M. Nilsson. DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. *Eur J Haematol.* 49(1):7-13, 1992.
- 35 S. Lethagen. Desmopressin--a haemostatic drug: state-of-the-art review. *Eur J Anaesthesiol Suppl.* 14:1-9, 1997.
- 36 S. Lethagen, L. Olofsson, K. Frick, E. Berntorp and S. Bjorkman. Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo. *Haemophilia.* 6(1):15-20, 2000.
- 37 M. Levi, M. E. Cromheecke, E. de Jonge, M. H. Prins, B. J. de Mol, E. Briet and H. R. Buller. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. *Lancet.* 354 (9194):1940-1947, 1999.

- 38 T. Lisman, F. W. Leebeek and P. G. de Groot. Haemostatic abnormalities in patients with liver disease. *J Hepatol.* 37(2):280-287, 2002.
- 39 P. M. Mannucci, M. Aberg, I. M. Nilsson and B. Robertson. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. *Br J Haematol.* 30(1):81-93, 1975.
- 40 P. M. Mannucci, G. Remuzzi, F. Pusineri, R. Lombardi, C. Valsecchi, G. Mecca and T. S. Zimmerman. Desamino-8-D-arginine vasopressin shortens the bleeding time in uremia. *N Engl J Med.* 308(1):8-12, 1983.
- 41 P. M. Mannucci, V. Vicente, L. Vianello, M. Cattaneo, I. Alberca, M. P. Coccato, E. Faioni and D. Mari. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. *Blood.* 67(4):1148-1153, 1986.
- 42 P. M. Mannucci, D. Bettega and M. Cattaneo. The development of tachyphylaxis in patients with haemophilia and von Willebrand's disease after repeated doses of desmopressin (DDAVP). *Br J Haematol.* 82(1):87-93, 1992.
- 43 P. M. Mannucci. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. *Blood.* 90(7):2515-2521, 1997.
- 44 P. M. Mannucci. Hemostatic drugs. *N Engl J Med.* 339(4):245-253, 1998.
- 45 P. M. Mannucci, M. T. Canciani, I. Forza, F. Lussana, A. Lattuada and E. Rossi. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. *Blood.* 98(9):2730-2735, 2001.
- 46 E. O. Meili. Ausgeprägte Blutungsneigung. *Haemostaseologie.* 24(4):221-233, 2004.
- 47 E. H. Moffat, J. C. Giddings and A. L. Bloom. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. *Br J Haematol.* 57(4):651-662, 1984.
- 48 R. D. Moore, L. R. Bone, G. Geller, J.A. Mamon, E. J. Stokes and D. M. Levine. Prevalence, detection and treatment of alcoholism in hospitalised patients. *JAMA.* 261(3): 403-407, 1989.

- 49 T. Neumann and C. Spies. Use of biomarkers for alcohol use disorders in clinical practice. *Addiction*. 98 (Suppl 2):81-91, 2003.
- 50 L. Oleksowicz, N. Bhagwato and M. DeLeon-Fernandez. Deficient activity of von Willebrand's factor-cleaving proteases in patients with disseminated malignancies. *Cancer Res*. 59(9):2244-2250, 1999.
- 51 F. W. Peter, C. Benkovic, T. Muehlberger, P. M. Vogt, H. H. Homann, C. Kuhnen, A. Wiebalck and H. U. Steinau. Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction. *Br J Haematol*. 117(3):658-663, 2002.
- 52 H. Pleym, R. Stenseth, A. Wahba, L. Bjella, A. Tromsdal, A. Karevold and O. Dale. Prophylactic treatment with desmopressin does not reduce postoperative bleeding after coronary surgery in patients treated with aspirin before surgery. *Anesth Analg*. 98(3):578-584, 2004.
- 53 R. A. Reiter, F. Mayr, H. Blazicek, E. Galehr, P. Jilma-Stohlavetz, H. Domanovits and B. Jilma. Desmopressin and platelets antagonize the in vitro platelet dysfunction induced by GP II_b/III_a inhibitors and aspirin. *Blood*. 102(13):4594-4599, 2003.
- 54 R. A. Reiter, P. Knöbl, K. Varadi and P. L. Turecek. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. *Blood*. 101(3):946-948, 2003.
- 55 S. C. Renaud and J. C. Ruf. Effects of alcohol on platelet functions. *Clin Chim Acta*. 246(1-2):77-89, 1996.
- 56 R. Rubin. Effect of ethanol on platelet function. *Alcohol Clin Exp Res*. 23(6):1114-1118, 1999.
- 57 R. Rychlik, C. Ernen, T. Pfeil und D. Daniel. Die Kosten des Alkoholismus in der Bundesrepublik Deutschland – Ergebnisse einer prospektiven Beobachtungsstudie. *Gesundheitsökonomie und Qualitätsmanagement*, 7(6):389-395, 2002.

- 58 M. Sakai, T. Watari, T. Miura, H. Maruyama, H. Koie, Y. Yamaya, A. Takeuchi and A. Hasegawa. Effects of DDAVP Administrated Subcutaneously in Dog with Aspirin-induced Platelet Dysfunction and Hemostatic Impairment due to Chronic Liver Diseases. *J Vet Med Sci.* 65(1):83-86, 2003.
- 59 M. Salaspuro. Carbohydrate-deficient transferrin as compared to other markers of alcoholism: a systematic review. *Alcohol.* 19(3):261-271, 1999.
- 60 E. W. Salzman, M. J. Weinstein, R. M. Weintraub, J. A. Ware, R. L. Thurer, L. Robertson, A. Donovan, T. Gaffney, V. Bertele and J. Troll. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. *N Engl J Med.* 314(22):1402-1406, 1986.
- 61 E. W. Salzman, M. J. Weinstein, D. Reilly and J. A. Ware. Adventures in hemostasis. Desmopressin in cardiac surgery. *Arch Surg.* 128(2):212-217, 1993.
- 62 D. Sarfaraz and C. L. Fraser. Effects of arginine vasopressin on cell volume regulation in brain astrocyte in culture. *Am J Physiol.* 276 (3 Pt 1):E596-E601, 1999.
- 63 H. Saß, H.U. Wittchen und M. Zaudig. Diagnostisches und Statistisches Manual Psychischer Störungen (DSM - IV). Hogrefe Verlag, 2. Auflage, 1998.
- 64 H. Schönfeld, T. Neumann, P. Sinha, C. Müller, LG Schmidt, W. J. Kox and C. D. Spies. Perioperative Diagnostik der Alkoholkrankheit bei männlichen Patienten mit einem Tumor des Gastrointestinaltraktes. *Suchtmed.* 1(1):39-46, 1999.
- 65 P. C. Sharpe. Biochemical detection and monitoring of alcohol abuse and abstinence. *Ann Clin Biochem.* 38(Pt 6):652-664, 2001.
- 66 J. Siekmann, P.L. Turecek and H.P. Schwarz. The determination of von Willebrand factor activity by collagen binding assay. *Haemophilia.* 4(Suppl. 3):15-24, 1998.
- 67 P. Sillanaukee, M. Aalto and K. Seppa. Carbohydrate-deficient transferrin and conventional alcohol markers as indicators for brief intervention among heavy drinkers in primary health care. *Alcohol Clin Exp Res.* 22(4):892-896, 1998.

- 68 C. D. Spies, A. Emadi, T. Neumann, L. Hannemann, A. Rieger, W. Schaffartzik, R. Rahmanzadeh, G. Berger, T. Funk and S. Blum. Relevance of carbohydrate-deficient transferrin as a predictor of alcoholism in intensive care patients following trauma. *J Trauma*. 39(4):742-748, 1995.
- 69 C. D. Spies, H. Rommelspacher, T. Winkler, C. Muller, G. Brummer, T. Funk, G. Berger, M. Fell, S. Blum, M. Specht, L. Hannemann and W. Schaffartzik. Beta-carbolines in chronic alcoholics following trauma. *Addict Biol*. 1(1):93-103, 1996.
- 70 C. D. Spies, A. Nordmann, G. Brummer, C. Marks, C. Conrad, G. Berger, N. Runkel, T. Neumann, C. Muller, H. Rommelspacher, M. Specht, L. Hannemann, H. W. Striebel and W. Schaffartzik. Intensive care unit stay is prolonged in chronic alcoholic men following tumor resection of the upper digestive tract. *Acta Anaesthesiol Scand*. 40(6):649-656, 1996.
- 71 C. D. Spies, B. Neuner, T. Neumann, S. Blum, C. Muller, H. Rommelspacher, A. Rieger, C. Sanft, M. Specht, L. Hannemann, H. W. Striebel and W. Schaffartzik. Intercurrent complications in chronic alcoholic men admitted to the intensive care unit following trauma. *Intensive Care Med*. 22(4):286-293, 1996.
- 72 C. D. Spies, N. Dubisz, T. Neumann, S. Blum, C. Muller, H. Rommelspacher, G. Brummer, M. Specht, C. Sanft, L. Hannemann, H. W. Striebel and W. Schaffartzik. Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. *Crit Care Med*. 24(3):414-422, 1996.
- 73 C. D. Spies, A. von Winterfeld, C. Müller, H. Rommelspacher, T. Neumann, C. Marks et al.. Reliability of Carbohydrate-Deficient Transferrin to Detect Chronic Alcohol misuse in Carcinoma Patients. *Eur Addict Res*. 2:156-162, 1996.
- 74 C. D. Spies and H. Rommelspacher. Alcoholwithdrawal in the Surgical Patient: Prevention and Treatment. *Anesth Analg*. 88(4):946-954, 1999.
- 75 C. D. Spies, H. Tonnesen, S. Andreasson, A. Helander and K. Conigrave. Perioperative morbidity and mortality in chronic alcoholic patients. *Alcohol Clin Exp Res*. 25(5 Suppl ISBRA):164S-170S, 2001.

- 76 C. D. Spies, M. J. Martin, C. Heymann, T. Neumann, L. Schmidt, F. Soost, B. Mazurek, B. Böhm, C. Marks, K. Helling, E. Lenzhuber, C. Müller and W. J. Kox. Preoperative Evaluation of Chronic Alcoholics Assesed for Surgery of the Upper Diggestive Tract. *Alcohol Clin Exp Res.* (26)6:836-840, 2002.
- 77 C. D. Spies, T. Neumann, H. Otter and W. J. Kox. Klinische Relevanz der Suchterkrankungen in operativen Einrichtungen. *Suchtmed.* 5(1):7-12, 2003.
- 78 H. Stibler. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. *Clin Chem.* 37(12):2029-2037, 1991.
- 79 H. Tonnesen, K. R. Petersen, L. Hojgaard, K. H. Stokholm, H. J. Nielsen, U. Knigge and H. Kehlet. Postoperative morbidity among symptom-free alcohol misusers. *Lancet.* 340(8815):334-337, 1992.
- 80 H. Tonnesen, M. Carstensen and P. Maina. Is carbohydrate deficient transferrin a useful marker of harmful alcohol intake among surgical patients? *Eur J Surg.* 165(6):522-527, 1999.
- 81 H. Tonnesen. [Alcohol, surgery and prevention]. *Ugeskr Laeger.* 161(24):3647-3649, 1999.
- 82 H. Tonnesen and H. Kehlet. Preoperative alcoholism and postoperative morbidity. *Br J Surg.* 86(7):869-874, 1999.
- 83 H. Tonnesen. The alcohol patient and surgery. *Alcohol Alcohol.* 34(2):148-152, 1999.
- 84 J. D. Tobias. Strategies for minimizing blood loss in orthopedic surgery. *Semin Hematol.* 41(1 Suppl 1):145-156, 2004.
- 85 U. M. Vischer and C. B. Wollheim. Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. *Thromb Haemost.* 77(6):1182-1188, 1997.
- 86 T. P. Whitehead, C. A. Clarke and A. G. Whitfield. Biochemical and haematological markers of alcohol intake. *Lancet.* 1(8071):978-981, 1978.

- 87 A. Y. Wong, M. G. Irwin, T. W. Hui, S. K. Fung, S. T. Fan and E. S. Ma. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. *Can J Anaesth.* 50(1):14-20, 2003.
- 88 T. Wun, T. G. Paglieroni and N. A. Lachant. Desmopressin stimulates the expression of P-selectin on human platelets in vitro. *J Lab Clin Med.* 126(4):401-409, 1995.
- 89 X. Yang, J. Disa and A. K. Rao. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. *Thromb Res.* 59(5):809-818, 1990.
- 90 J. W. Yarnell, P. M. Sweetnam, A. Rumley and G. D. Lowe. Lifestyle factors and coagulation activation markers: the Caerphilly Study. *Blood Coagul Fibrinolysis.* 12(8):721-728, 2001.
- 91 Z. R. Zeigler, A. Megaludis and D. S. Fraley. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. *Am J Hematol.* 39(2):90-95, 1992.
- 92 G. Zellin, L. Rasmusson, J. Palsson and K. E. Kahnberg. Evaluation of hemorrhage depressors on blood loss during orthognathic surgery: a retrospective study. *J Oral Maxillofac Surg.* 62(6):662-666, 2004.